PYC Therapeutics (ASX:PYC) - Hisse Senedi Fiyatı, Haberler ve Analizler

PYC Stoklara Genel Bakış

PYC temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 15.56% oranında artması öngörülüyor

Risk Analizi

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

PYC Therapeutics Limited Rakipler

Actinogen Medical

ASX:ACW

AU$73.6m

Radiopharm Theranostics

ASX:RAD

AU$56.5m

Beroni Group

NSX:BTG

AU$75.9m

Orthocell

ASX:OCC

AU$149.4m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti PYC Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$1.83
52 Haftanın En Yüksek Seviyesi	AU$2.10
52 Haftanın En Düşük Seviyesi	AU$0.73
Beta	0.60
11 Aylık Değişim	-8.50%
3 Aylık Değişim	52.50%
1 Yıllık Değişim	140.79%
33 Yıllık Değişim	30.71%
5 Yıllık Değişim	200.00%
Halka arzdan bu yana değişim	-29.62%

Son Haberler & Güncellemeler

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Oct 25

Recent updates

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Feb 20

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

Jan 26

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

Dec 22

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Nov 17

Hissedar Getirileri

	PYC	AU Biotechs	AU Pazar
7D	-1.1%	-3.6%	1.5%
1Y	140.8%	10.0%	17.2%

Getiri vs. Endüstri: PYC geçen yıl % 10 oranında getiri sağlayan Australian Biotechs sektörünü aştı.

Getiri vs Piyasa: PYC geçen yıl % 17.2 oranında getiri sağlayan Australian Piyasasını aştı.

Fiyat Oynaklığı

Is PYC's price volatile compared to industry and market?
PYC volatility
PYC Average Weekly Movement	12.4%
Biotechs Industry Average Movement	9.7%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

İstikrarlı Hisse Senedi Fiyatı: PYC son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: PYC 'nin haftalık oynaklığı ( 12% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2001	n/a	Rohan Hockings	pyctx.com

Bir ilaç geliştirme şirketi olan PYC Therapeutics Limited, Avustralya'da genetik hastalıkların tedavisi için yeni RNA terapötiklerinin keşfi ve geliştirilmesiyle ilgilenmektedir. Şirket, retinitis pigmentosa tip 11 tedavisi için Faz 1 klinik çalışması olan bir ilaç programı olan VP-001; kör edici göz hastalığının tedavisi için bir ilaç adayı olan PYC-001; ciddi bir nörogelişimsel bozukluğun tedavisi için bir ilaç programı olan PYC-002; ve otozomal dominant polikistik böbrek hastalığını tedavi etmek için endike olan PYC-003'ü sunmaktadır. PYC Therapeutics Limited, nörodejeneratif bozukluklar alanında ilaç keşfi ve geliştirme çabalarını desteklemek için Murdoch Üniversitesi ile akademik-endüstri işbirliklerine sahiptir.

PYC Therapeutics Limited Temel Bilgiler Özeti

PYC Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
PYC temel i̇stati̇sti̇kler
Piyasa değeri	AU$886.56m
Kazançlar(TTM)	-AU$37.73m
Gelir(TTM)	AU$22.06m

38.7x

P/S Oranı

-22.6x

F/K Oranı

PYC aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
PYC gelir tablosu (TTM)
Gelir	AU$22.06m
Gelir Maliyeti	AU$0
Brüt Kâr	AU$22.06m
Diğer Giderler	AU$59.78m
Kazançlar	-AU$37.73m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.081
Brüt Marj	100.00%
Net Kâr Marjı	-171.02%
Borç/Özkaynak Oranı	0%

PYC uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

PYC Stoklara Genel Bakış

Ödüller

Risk Analizi

PYC Therapeutics Limited Rakipler

ASX:ACW

AU$73.6m

ASX:RAD

AU$56.5m

NSX:BTG

AU$75.9m

ASX:OCC

AU$149.4m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New minor risk - Market cap size

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Price target increased by 8.2% to AU$0.33

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Price target increased by 9.1% to AU$0.30

Insufficient new directors

Recent updates

New minor risk - Market cap size

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Price target increased by 8.2% to AU$0.33

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Price target increased by 9.1% to AU$0.30

Insufficient new directors

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Price target decreased by 15% to AU$0.29

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

New minor risk - Share price stability

We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

CEO & Director exercised options to buy AU$1.6m worth of stock.

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Non-Executive Chair of the Board recently bought AU$81k worth of stock

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

PYC Therapeutics Limited Temel Bilgiler Özeti

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease Autosomal Dominant Optic Atrophy